Drug-resistant tuberculosis in New York City: Lessons to remember

Clinical Infectious Diseases

Volumn 42, Issue 12, 2006, Pages 1711-1712

  Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; DRUG MONITORING; HUMAN; INCIDENCE; INFECTION CONTROL; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; TUBERCULOSIS; UNITED STATES;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NEW YORK CITY; TUBERCULOSIS, PULMONARY;

EID: 33744792019     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504332     Document Type: Note

References (15)

1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2005.349. Geneva: World Health Organization, 2005.
3. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745-9.
4. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521-6.
5. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City: turning the tide. N Engl J Med 1995; 333: 229-33.
6. Centers for Disease Control and Prevention. Trends in tuberculosis-United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54: 245-9.
7. Munsiff SS, Li J, Cook SV, et al Trends in drug-resistant Mycobacterium tuberculosis infection in New York City, 1991-2003. Clin Infect Dis 2006; 42:1702-10 (in this issue).
8. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945-51.
9. Moore RD, Chaulk CP, Griffiths R, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154: 1013-9.
10. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/ IUATLD global project on anti-tuberculosis drug resistance surveillance. WHO/HTM/TB/ 2004 343. Geneva: World Health Organization, 2004.
11. Weis SE, Slocum PC, Blais FX, et al. The effect of directly-observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84.
12. Bloom BR, Salomon JA. Enlightened self-interest and the control of tuberculosis. N Engl J Med 2005; 353:1057-9.
13. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353:1008-20.
14. Bozeman L, Burman W, Gordin F, et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-91.
15. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37:1448-52.